Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

NCT03372837 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Interventions

DRUG: Rituximab

Sponsor

SymBio Pharmaceuticals